Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.64 |
| ▸ | MAP2K4 | P45985 | 11/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | MAPK6 | Q16659 | 2/20 | 0.50 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.50 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | HTR7 | P34969 | 1/20 | 0.49 |
| ▸ | HTR6 | P50406 | 1/20 | 0.49 |
| ▸ | ITK | Q08881 | 2/20 | 0.45 |
| ▸ | MAP2K7 | O14733 | 2/20 | 0.45 |
| ▸ | WNT1 | P04628 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13727305 | 0.83 | HTR2C (0.50) | HTR2AHTR2CHTR6DRD2 | |
| SCHEMBL24331228 | 0.80 | HTR2C (0.60) | HTR2AMAP2K4HTR2CHTR6ITK | |
| SCHEMBL25293881 | 0.78 | HTR2A (1.00) | HTR2AMAP2K4MAPK1MAPK6MAPKAPK2 | |
| SCHEMBL5093538 | 0.74 | HTR6 (0.45) | HTR2AHTR2CHTR7HTR6DRD2 | |
| SCHEMBL5845143 | 0.73 | HTR2C (0.65) | HTR2AMAPK1HTR2CHTR7HTR6 | |
| SCHEMBL22070134 | 0.72 | LRRK2 (0.43) | HTR2AMAP2K4MAPK1MAPK6MAPKAPK2 | |
| SCHEMBL6811623 | 0.72 | KHK (0.47) | HTR2AHTR2CHTR7HTR6DRD2 | |
| SCHEMBL25293324 | 0.69 | CHEK1 (0.46) | HTR2AHTR2CHTR7HTR6DRD2 | |
| SCHEMBL25769853 | 0.69 | HTR2A (1.00) | HTR2AMAP2K4MAPK1MAPK6MAPKAPK2 | |
| SCHEMBL27191587 | 0.69 | MAP2K4 (1.00) | HTR2AMAP2K4MAPK1MAPK6MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7335660-B2 | Isochroman compounds for treatment of CNS disorders | ELI LILLY AND COMPANY (US) | 2008-02-26 | — | — | US | disclosed |
| EP-1458703-B1 | ISOCHROMAN COMPOUNDS FOR TREATMENT OF CNS DISORDERS | LILLY CO ELI (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20050014750-A1 | Isochroman compounds for treatment of cns disorders | ELI LILLY AND COMPANY | 2005-01-20 | — | — | US | disclosed |
| EP-1409476-B1 | PHARMACEUTICAL COMPOUNDS WITH SEROTONIN RECEPTOR ACTIVITY | LILLY CO ELI (US) | 2004-12-15 | — | — | EP | disclosed |
| EP-1458703-A1 | ISOCHROMAN COMPOUNDS FOR TREATMENT OF CNS DISORDERS | ELI LILLY AND COMPANY (US) | 2004-09-22 | — | — | EP | disclosed |
| US-20040180883-A1 | Pharmaceutical compounds with serotonin receptor activity | GILMORE JEREMY (GB) | 2004-09-16 | — | — | US | disclosed |
| US-20040122001-A1 | Pharmaceutical compounds | ELI LILLY AND COMPANY | 2004-06-24 | — | — | US | disclosed |
| EP-1345930-A2 | PHARMACEUTICAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2003-09-24 | — | — | EP | disclosed |
| WO-2003053948-A1 | ISOCHROMAN COMPOUNDS FOR TREATMENT OF CNS DISORDERS | ELI LILLY AND COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
| WO-2002050067-A2 | PHARMACEUTICAL HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180883-A1 | Pharmaceutical compounds with serotonin receptor activity | HTR1A, HTR5A, HTR1E | HTR2A 5/4885MAP2K4 4416/4885MAPK1 3694/4885 |
| US-20050014750-A1 | Isochroman compounds for treatment of cns disorders | INA, CNR2, CNR1 | HTR2A 131/4885MAP2K4 4194/4885MAPK1 3140/4885 |
| US-20040122001-A1 | Pharmaceutical compounds | CYP2D6, LPXN, CYP1B1 | HTR2A 2038/4885MAP2K4 4646/4885MAPK1 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.